ASX ANNOUNCEMENT 12 October 2026 Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889 Not for release to US wire services or distribution in the United States Non-Compliance with Listing Rule 10.11 Sydney, Australia – 12...
Non-Compliance with Listing Rule 10.11
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The company disclosed that it exceeded the maximum number of shares and options approved by shareholders during a recent extraordinary general meeting. To address this breach, the directors will sell the excess shares on the market and donate the proceeds to charity, while the excess options will be cancelled. The company reaffirms its commitment to comply with ASX Listing Rules and improve corporate governance practices going forward.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
- RAD Completes Meeting with US FDA for Development of RAD101
- Notification of cessation of securities - RAD
- Change of Director's Interest Notice (RC)
- Appendix 4G and Corporate Governance Statement
Later from Radiopharm Theranostics
- Change of Director's Interest Notices x 4
- Notification regarding unquoted securities - RAD
- Radiopharm receives $8M advance on FY26 R&D tax incentive
- Notice of Annual General Meeting/Proxy Form
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics